Livasupril

**Livasupril** is an oral fixed-dose lipid-lowering combination developed by Hanlim Pharm containing micronized fenofibrate 160 mg and pitavastatin calcium 2 mg. Fenofibrate is converted to fenofibric acid, a peroxisome proliferator-activated receptor alpha agonist that improves triglyceride-rich lipoprotein metabolism, while pitavastatin competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase to reduce hepatic cholesterol synthesis and increase LDL clearance. The product has been studied for mixed or complex dyslipidemia, including a completed Phase 3 trial comparing the combination with pitavastatin monotherapy. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT02250976))

Brand names

Livasupril

Other names

fenofibrate + pitavastatinmicronized fenofibrate + pitavastatin calcium